Vancomycin Serum Concentration Monitoring: A Continued Debate

Edwards DJ Pancorbo S . Routine monitoring of serum vancomycin concentrations: Waiting for proof of its value. Clin Pharm 1987; 6: 652–8.

Rodvold KA Zokufa H Rotschafer JC . Routine monitoring of serum vancomycin concentrations: Can waiting be justified? Clin Pharm 1987; 6: 655–8.

Cantu TG Yamanaka-Yuen NA Lietman PS . Vancomycin therapeutic drug monitoring: Is it necessary? Clin Infect Dis 1994; 18: 533–43.

Moellering RC . Monitoring serum vancomycin levels: Climbing the mountain because it is “there?” (editorial) Clin Infect Dis 1994; 18: 544–6.

Freeman CD Quintiliani R Nightingale CH . Vancomycin therapeutic drug monitoring: Is it necessary? Ann Pharmacother 1993; 27: 594–8.

Pryka RD Rodvold KA Erdman SM . An updated comparison of drug dosing methods. Part IV: Vancomycin. Clin Pharmacokinet 1991; 20: 463–76.

Peck CC D'Argenio DZ Rodman JH . Analysis of pharmacokinetic data for individualizing drug dosing regimens. In: Evans WE Schentag JJ Jusko WJ eds. Applied pharmacokinetics: Principles of therapeutic drug monitoring. Vancouver, WA: Applied Therapeutics, 1992: 3–31.

Welty TE Copa AK . Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994; 28: 1335–9.

Schaad UB McCracken GH Nelson JD . Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96: 119–26.

Sorrell TC Packham DR Shanker S Foldes M Munro R . Vancomycin therapy for methicillin-resistant Staphylococcus aureus Ann Intern Med 1982; 97: 344–50.

Lisby-Sutch SM Nahata MC . Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988; 35: 637–42.

Farber BF Moellering RC . Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138–41.

Traber PG Levine DP . Vancomycin ototoxicity in a patient with normal renal function. Ann Intern Med 1981; 95: 458–60.

Mellor JA Kingdom J Cafferkey M Keane CT . Vancomycin toxicity: A prospective study. J Antimicrob Chemother 1985; 15: 773–80.

Rybak MJ Albrecht LM Boike SC Chandrasekar PH . Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679–87.

Cimino MA Rostein C Slaughter RL Emrich LJ . Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987; 83: 1091–7.

Moellering RC Krogstad DJ Greenblatt DJ . Vancomycin therapy in patients with impaired renal function: A nomogram for dosage. Ann Intern Med 1981; 94: 343–6.

Lake KD Peterson CD . A simplified dosing method for initiating vanomycin therapy. Pharmacotherapy 1985; 5: 340–4.

Lake KD Peterson CD . Evaluation of a method for initiating vancomycin therapy: Experience in 205 patients. Pharmacotherapy 1988; 8: 284–6.

McCormack JP Lynd LD Pfeifer NM . Vancomycin cost containment through a therapeutic and pharmacokinetic drug monitoring service. Can J Hosp Pharm 1989; 42: 3–9.

Uaamnuichai M Day RB Brater DC . Bayesian and least-squares methods for vancomycin dosing. Am J Med Sci 1987; 294: 100–4.